

DART – Reducing Treatment

Burden DBS Post AI remote immunoglobulin Replacement
monitoring (DART)



Stephen Jolles
Immunodeficiency Centre for Wales
Cardiff, UK

Contents

- Of Hot Chocolate and Churros
- DART Project
- Results
- Patient Feedback
- Health Economics
- Neurology
- Where next?



Dried Blood Spots (DBS)

DBS used in the Newborn Screening programme for early identification of 9 genetic disorders

Traditional Guthrie Card:

- **Semi-quantitative**
 - Lack of volumetric control and haematocrit effect
- Risk of under- and over-fill
- Risk of sample contamination

Guthrie Card



Name: _____

Date: _____


Capitainer® B 50

- **Quantitative**
 - Accurately collects 50 µl whole blood from a finger prick
 - Designed to minimize under- and over-fill
- No drying step required
- Protected from contamination
- Patients can see if correctly filled



Capitainer[®]B50

- ▶ 2x50μL of whole blood
- ▶ Volume precision < 3 %
- ▶ Sample protection
- ▶ Successful sampling indication
- ▶ Pre-cut sample discs
- ▶ Enables larger sample volume




Capitainer[®]B is CE-marked, registered as an IVD product according to the IVD Regulation (EU) 2017/746 and registered with the US FDA as a Device Class 1.

DART Aim:

To assess the **accuracy, ease of use and acceptability** of DBS sampling to monitor IgG levels of patients with antibody deficiency receiving immunoglobulin replacement therapy (IgRT).

		All patients (n=43)
Sex	Male	20 (47%)
	Female	23 (53%)
Age	20-29	6 (14%)
	30-39	6 (14%)
	40-49	6 (14%)
	50-59	10 (23%)
	60-69	8 (19%)
	70-79	5 (12%)
	80+	2 (5%)
Immunological diagnosis	CVID	26 (62%)
	Secondary antibody deficiency	6 (14%)
	IgA deficiency	3 (7%)
	XLA	2 (5%)
	SCID	1 (2%)
	Combined immunodeficiency	2 (5%)
	Wiskott Aldrich Syndrome	1 (2%)
	Other	2 (5%)
Immunoglobulin replacement therapy administration	Subcutaneous	42 (98%)
	Intravenous	1 (2%)



VS



Traditional blood test Capitainer blood spot

Standard of Care




- Monitoring of patients on IgRT – Hospital and Home
- Clinics 6 monthly – if unwell more frequent
- PID Clinics have a Nursing and Medical review
- Blood testing in clinic (may not time with trough for IVIg)
- Send in Blood testing
- Home IgRT – Immunology Nurse home visit every 2 years


DART - what we did in clinic

- Patients were recruited from Immunodeficiency Clinic appointments
- Training in the use of the Capitainer took place in clinic
- First parallel samples Capitainer and Liquid blood collected
- Patients were provided with the standard of care blood collection kits and also the Capitainer kits
- Routine monitoring 3-4 monthly of both methods for 1 year
- Questionnaires with each send in of samples
- Early feedback from the training enabled modification including 'finger tourniquet' and milking technique


1




2




3




4




5



6




A little something for the Planet



Modified Optilite Protocol


- Capitainer spot dilution means that normal Ig protocol can't be used
- Need to limit on board dilution
- Optilite CSF protocol was used for IgG, IgA and IgM




A close-up, shallow depth-of-field photograph of a white plastic rack holding several glass test tubes. The tubes are filled with a red liquid, likely blood, and have white caps. The liquid levels vary slightly between tubes, creating a gradient effect. The background is blurred, showing more tubes in the distance.

Results Capitainer vs Liquid Blood

Capitaine r vs Liquid Blood - IgG






Capitaine r vs Liquid Blood - IgM




Epigenetic Immune Cell Quantification

Technology is based on DNA methylation:

- CpG dinucleotides
- Stable, long-term modification of DNA
- Regulatory function of gene expression




Epigenetic Immune Cell Quantification



EPIMUNE[™]
DIAGNOSTICS

i.Mune TBNK – Overview of Test Procedure

Sample
Types




Lysis/
Bisulfite
Conversion/
DNA Isolation



qPCR




Quantification




EPIMUNE[™]
DIAGNOSTICS


Lymphocyte subsets




Pearson's $r=0.865$ $p<0.0001$




Pearson's $r=0.872$ $p<0.0001$



Pearson's $r=0.816$ $p<0.0001$



Pearson's $r=0.96$ $p<0.0001$



Pearson's $r=0.864$ $p<0.0001$

Neurology Multiple Sclerosis (MS) Project

- The Neurology Unit at UHW looks after around 1000 MS patients
- There is increasing use of B cell ablative therapies eg Ocrelizumab
- Dosing is usually every six months
- B cells are usually absent
- Ongoing collaboration with Neurology on SAD

Neurology (MS – antiCD20) and Immunodeficiency



EPIMUNE[™]
DIAGNOSTICS


Capitainer samples




Whole blood samples



Methylated DNA



Flow cytometry



Immunodeficiency
Patient Questionnaires




Dried blood vs whole blood comparison

Short Report


Home-sampling of B cells using quantitative dried blood spots to enable tailored therapeutic re-dosing of anti-CD20 therapies

Emma C Tallantyre , Emily Jacob, Laura Davies, Samantha Loveless, Emily Carne, Kath Bramhall, Janika Schulze, Stuart J Moat* and Stephen Jolles*

Multiple Sclerosis Journal
1–4
DOI: 10.1177/
13524585251330962
© The Author(s), 2025.
Article reuse guidelines:
sagepub.com/journals-
permissions



[normal range 50 – 500 x10⁶ cells/L]



		Dried blood spot			
		CD19 ≤10		Total	
		Yes	No		
Whole blood CD19 ≤10	Yes	14	0	14	Sensitivity = 100%
	No	0	36	36	Specificity = 100%
	Total	14	36	50	

Personalised dosing of antiCD20




Standard
dosing



Ocrevus

Personalised
dosing



Blood tests of B-cells 4-6 weekly (once dose due) every cycle

Other Neurological uses of rituximab

- Vasculitis
- Neuromyelitis optica
- MOG antibody disease
- Autoantibody mediated encephalitis
- Immune mediated neuropathy



EPIMUNE™
DIAGNOSTICS

Other Specialties use of B cell ablation

- Rheumatology
- Respiratory
- Renal
- Haematology
- Other



EPIMUNE™
DIAGNOSTICS


Combined B cell and SAD monitoring

- B cells
- IgG, IgA and IgM
- Functional antibodies



EPIMUNE™
DIAGNOSTICS

Preferred method of blood sampling



But - most of it was

"It is less intrusive in regards to the needles, less risk of infections I wouldn't have to sit in the GP waiting rooms or travel on public transport or get a lift from a family member."

Participant 5


"Today feeling anxious as I set off for my bloods to be done as I am thinking about what problems will occur as usual".

Participant 15

Lost in Translation

- Challenges in translating an approach into the routine service
- Requires capital and staff investment
- Remember service contracts
- Initial cost per sample may be higher as numbers are smaller
- Difficult to persuade if savings are made elsewhere eg in primary care or a neurology drug budget
- Or are less tangible ie for patients

Pre-Clinic Blood Testing



Pre Clinic Bloods

- For new referrals into Immunodeficiency clinic
- If appropriate – blood boxes and request forms are sent to patients
- This allows the results to be assessed and vaccinations with follow up bloods to be arranged ahead of clinic
- The results and next steps can then be discussed with the patient in clinic
- Aims to speed up the diagnostic/assessment process and reduce clinic appointment burden

Conclusions



- The combination of quantitative DBS linked to mDNA and protein assays may enable Immunoglobulin and lymphocyte analysis in both Immunology and other settings
- Potential for reduced treatment/monitoring burden for patients
- Initial study was overall well received by patients
- Savings to drug costs may be made in Neurology (other)
- Potential reduction in the numbers of patients with secondary antibody deficiency
- Translation and service change has its challenges



Thank you